Development of New Drugs for Autoimmune Hemolytic Anemia

Autoimmune hemolytic anemia (AIHA) is a rare disorder characterized by the autoantibody-mediated destruction of red blood cells, and treatments for it still remain challenging. Traditional first-line immunosuppressive therapy, which includes corticosteroids and rituximab, is associated with adverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Zhengrui, Murakhovskaya, Irina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147507/
https://www.ncbi.nlm.nih.gov/pubmed/35631621
http://dx.doi.org/10.3390/pharmaceutics14051035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147507/
https://www.ncbi.nlm.nih.gov/pubmed/35631621
http://dx.doi.org/10.3390/pharmaceutics14051035

Ejemplares similares